See What HealthDay Can Do For You
Contact Us

TAK-875 Improves Glycemic Control in Type 2 Diabetes

Targeting of free fatty acid receptor 1 beneficial for patients unresponsive to diet or metformin

MONDAY, Feb. 27 (HealthDay News) -- For patients with type 2 diabetes who do not respond to diet or metformin treatment, selective pharmacological activation of the free fatty acid receptor 1 (FFAR1) by TAK-875 improves glycemic control, according to a phase 2 study published online Feb. 27 in The Lancet.

Charles F. Burant, M.D., from the University of Michigan in Ann Arbor, and colleagues randomly assigned 426 patients with type 2 diabetes who had not responded to diet or metformin treatment to receive TAK-875 (303 patients), placebo (61), or glimepiride (62) for 12 weeks.

The researchers found that, at week 12, there were significant least-squares mean reductions in hemoglobin A1c from baseline in all patients in the TAK-875 and glimepiride groups compared with placebo. For TAK-875 and placebo, the treatment-emergent hypoglycemic events rates were similar (2 and 3 percent, respectively), but the rate was significantly higher in the glimepiride group (19 percent). There was a similar incidence of treatment-emergent adverse events in the TAK-875 and placebo groups (49 and 48 percent, respectively), but more events were seen in the glimepiride group (61 percent).

"TAK-875 significantly improved glycemic control in patients with type 2 diabetes with minimum risk of hypoglycemia. The results show that activation of FFAR1 is a viable therapeutic target for treatment of type 2 diabetes," the authors write.

All of the authors disclosed ties to Takeda Global Research and Development, which funded the study and manufactures TAK-875.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.